News & Blog

Cell Therapy in CNS: Why now?

Immunitas Therapeutics Appoints Lynette Herscha as Chief Operating Officer

Multi-omics Startup Pleno Inc. Announces $15 Million in Pre-Series A Funding

ProJenX Names Life Sciences Industry Veteran Stan E. Abel as CEO

Aspen Neuroscience Announces $147.5 Million Series B Financing, Led by GV, LYFE Capital and Revelation Partners

How Lessons Learned During COVID Will Shape the Future of Early Cancer Detection

Aspen Neuroscience Launches First Patient Screening Study for Planned Clinical Trial of Personalized Cell Replacement in Parkinson’s Disease

ALS News Today: ProJenX Launches, Will Develop ALS Therapy Prosetin

ProJenX Announces First Person Dosed in Phase 1 Study of Prosetin

ProJenX launches to advance novel, targeted therapies for ALS and other brain diseases